Table 6 QTc of patients in H group and HP group under various risk factors.
From: Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
H group | HP group | P value | H group | HP group | P value | ||
|---|---|---|---|---|---|---|---|
N = 55 | N = 40 | N = 49 | N = 17 | ||||
Age ≥ 60 | CAD | ||||||
Baseline | 414.23 ± 27.68 | 420.88 ± 28.53 | 0.247 | Baseline | 412.78 ± 30.04 | 408.50 ± 30.35 | 0.086 |
3m | 425.26 ± 30.92 | 436.52 ± 27.41 | 0.153 | 3m | 434.38 ± 33.25 | 441.24 ± 31.92 | 0.059 |
6m | 436.93 ± 33.21 | 442.21 ± 30.67 | 0.114 | 6m | 427.78 ± 34.14 | 443.89 ± 38.37 | 0.001* |
9m | 434.37 ± 31.29 | 438.68 ± 26.54 | 0.274 | 9m | 426.54 ± 31.38 | 448.26 ± 35.69 | < 0.001* |
12m | 438.95 ± 28.47 | 443.68 ± 29.55 | 0.133 | 12m | 430.12 ± 30.17 | 447.63 ± 34.42 | < 0.001* |
N = 91 | N = 95 | N = 184 | N = 110 | ||||
|---|---|---|---|---|---|---|---|
Left chest wall radiotherapy | Anthracyclines | ||||||
Baseline | 409.11 ± 33.26 | 409.99 ± 31.47 | 0.844 | Baseline | 414.78 ± 33.89 | 416.79 ± 30.73 | 0.417 |
3m | 424.79 ± 36.85 | 426.52 ± 32.08 | 0.326 | 3m | 426.32 ± 35.94 | 437.81 ± 32.68 | < 0.001* |
6m | 437.45 ± 35.93 | 438.57 ± 38.81 | 0.613 | 6m | 431.67 ± 31.77 | 451.85 ± 29.61 | < 0.001* |
9m | 428.12 ± 38.26 | 431.91 ± 41.22 | 0.109 | 9m | 419.17 ± 37.26 | 443.47 ± 31.87 | < 0.001* |
12m | 431.88 ± 40.32 | 436.44 ± 39.14 | 0.095 | 12m | 420.84 ± 38.28 | 448.24 ± 34.92 | < 0.001* |
